Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Eribulin + Pembrolizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Eribulin||Halaven||Antimicrotubule Agent 13|
|Pembrolizumab||Keytruda||MK-3475||Immune Checkpoint Inhibitor 136 PD-L1/PD-1 antibody 79||Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, CD274 (PD-L1)-expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, cervical cancer, and triple-negative breast cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib or lenvatinib in RCC, with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemotherapy for patients with esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, and in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-expressing (CPS>=1) cervical cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CD274 positive||triple-receptor negative breast cancer||predicted - sensitive||Eribulin + Pembrolizumab||Phase Ib/II||Actionable||In a Phase I/II trial, Keytruda (pembrolizumab) and Eribulin combination therapy demonstrated safety and clinical activity in patients with metastatic triple-negative breast cancer, patients with CD274 (PD-L1)-positive tumors achieved better objective response rate (28.4% vs 17.3%), median progression-free survival (4.2 vs 3.9 months), and overall survival (16.3 vs 15.2 months) compared to patients with CD274 (PD-L1)-negative tumors (PMID: 33727258; NCT02513472).||33727258|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03899805||Phase II||Eribulin + Pembrolizumab||A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas||Active, not recruiting||USA||0|
|NCT03051659||Phase II||Eribulin Eribulin + Pembrolizumab||A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer||Active, not recruiting||USA||0|
|NCT02513472||Phase Ib/II||Eribulin + Pembrolizumab||Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1)||Completed||USA||0|